JAZZ PHARMACEUTICALS PLC (JAZZ)
IE00B4Q5ZN47 - Common Stock
Overall JAZZ gets a fundamental rating of 5 out of 10. We evaluated JAZZ against 198 industry peers in the Pharmaceuticals industry. While JAZZ has a great profitability rating, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on JAZZ.
1. Profitability
1.1 Basic Checks
In the past year JAZZ was profitable.
In the past year JAZZ had a positive cash flow from operations.
In multiple years JAZZ reported negative net income over the last 5 years.
Each year in the past 5 years JAZZ had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 3.64%, JAZZ belongs to the best of the industry, outperforming 88.27% of the companies in the same industry.
JAZZ has a Return On Equity of 11.10%. This is amongst the best in the industry. JAZZ outperforms 89.29% of its industry peers.
The Return On Invested Capital of JAZZ (4.64%) is better than 83.16% of its industry peers.
JAZZ had an Average Return On Invested Capital over the past 3 years of 2.97%. This is significantly below the industry average of 16.40%.
The 3 year average ROIC (2.97%) for JAZZ is below the current ROIC(4.64%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 11.1% | ||
| ROIC | 4.64% |
ROA(3y)-0.37%
ROA(5y)2.4%
ROE(3y)-1.49%
ROE(5y)3.77%
ROIC(3y)2.97%
ROIC(5y)4.79%
1.3 Margins
With an excellent Profit Margin value of 10.82%, JAZZ belongs to the best of the industry, outperforming 88.27% of the companies in the same industry.
JAZZ's Profit Margin has declined in the last couple of years.
JAZZ has a Operating Margin of 15.09%. This is amongst the best in the industry. JAZZ outperforms 86.73% of its industry peers.
JAZZ's Operating Margin has declined in the last couple of years.
JAZZ has a better Gross Margin (88.64%) than 91.33% of its industry peers.
JAZZ's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.09% | ||
| PM (TTM) | 10.82% | ||
| GM | 88.64% |
OM growth 3Y-7.54%
OM growth 5Y-13.14%
PM growth 3Y2.34%
PM growth 5Y-14.48%
GM growth 3Y-1.83%
GM growth 5Y-1.08%
2. Health
2.1 Basic Checks
JAZZ has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for JAZZ has been reduced compared to 1 year ago.
The number of shares outstanding for JAZZ has been increased compared to 5 years ago.
The debt/assets ratio for JAZZ has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.35, we must say that JAZZ is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.35, JAZZ is in the better half of the industry, outperforming 63.27% of the companies in the same industry.
JAZZ has a debt to FCF ratio of 5.45. This is a neutral value as JAZZ would need 5.45 years to pay back of all of its debts.
The Debt to FCF ratio of JAZZ (5.45) is better than 84.18% of its industry peers.
JAZZ has a Debt/Equity ratio of 1.37. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.37, JAZZ is not doing good in the industry: 78.06% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.37 | ||
| Debt/FCF | 5.45 | ||
| Altman-Z | 1.35 |
ROIC/WACC0.72
WACC6.43%
2.3 Liquidity
JAZZ has a Current Ratio of 2.24. This indicates that JAZZ is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of JAZZ (2.24) is worse than 63.27% of its industry peers.
JAZZ has a Quick Ratio of 1.85. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of JAZZ (1.85) is worse than 63.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.24 | ||
| Quick Ratio | 1.85 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 39.53% over the past year.
The Earnings Per Share has been growing slightly by 6.00% on average over the past years.
JAZZ shows a small growth in Revenue. In the last year, the Revenue has grown by 4.77%.
Measured over the past years, JAZZ shows a quite strong growth in Revenue. The Revenue has been growing by 15.19% on average per year.
EPS 1Y (TTM)39.53%
EPS 3Y13.68%
EPS 5Y6%
EPS growth Q2Q7271.43%
Revenue 1Y (TTM)4.77%
Revenue growth 3Y17.5%
Revenue growth 5Y15.19%
Revenue growth Q2Q4.1%
3.2 Future
The Earnings Per Share is expected to grow by 3.77% on average over the next years.
The Revenue is expected to grow by 4.08% on average over the next years.
EPS Next Y5.59%
EPS Next 2Y8.24%
EPS Next 3Y6.63%
EPS Next 5Y3.77%
Revenue Next Year7.08%
Revenue Next 2Y7.09%
Revenue Next 3Y6.11%
Revenue Next 5Y4.08%
3.3 Evolution
The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
JAZZ is valuated cheaply with a Price/Earnings ratio of 6.00.
Compared to the rest of the industry, the Price/Earnings ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 95.92% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of JAZZ to the average of the S&P500 Index (24.76), we can say JAZZ is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 5.68, the valuation of JAZZ can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of JAZZ indicates a rather cheap valuation: JAZZ is cheaper than 96.94% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.26. JAZZ is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6 | ||
| Fwd PE | 5.68 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, JAZZ is valued cheaper than 86.22% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, JAZZ is valued cheaply inside the industry as 94.90% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.53 | ||
| EV/EBITDA | 8.86 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
JAZZ has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.07
PEG (5Y)1
EPS Next 2Y8.24%
EPS Next 3Y6.63%
5. Dividend
5.1 Amount
JAZZ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
JAZZ PHARMACEUTICALS PLC
NASDAQ:JAZZ (4/19/2024, 7:00:02 PM)
After market: 110.35 +0.41 (+0.37%)109.94
+0.67 (+0.61%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap6.85B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6 | ||
| Fwd PE | 5.68 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.07
PEG (5Y)1
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.64% | ||
| ROE | 11.1% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 15.09% | ||
| PM (TTM) | 10.82% | ||
| GM | 88.64% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.37 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.24 | ||
| Quick Ratio | 1.85 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)39.53%
EPS 3Y13.68%
EPS 5Y
EPS growth Q2Q
EPS Next Y5.59%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)4.77%
Revenue growth 3Y17.5%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y